Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
SYDNEY, Australia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-Infectives, today announced it signed a Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a leading Indonesian biomedical organization, to accelerate the clinical development of Recce’s anti-infective portfolio across Indonesia, with the aim of addressing the critical global health challenge of antimicrobial resistance (AMR).
“The global health challenge of antimicrobial resistance is a pressing issue on the world stage,” said Budi Sadikin, Indonesian Minister of Health. “Indonesia welcomes collaborative initiatives and supports efforts to combat antimicrobial resistance, including the development of innovative therapeutics for infectious diseases.”
This is a historically significant bilateral initiative supported by the Australian and Indonesian governments. In a meeting together with Senior Executives from Recce and Etana, Her Excellency Penny Williams PSM, the Australian Ambassador to Indonesia, the Indonesian Minister of Health, Budi Sadikin, and the Head of the National Research and Innovation Agency (BRIN) were all in full support of this initiative.
Recce will collaborate with nationally selected biotech sponsor Etana to advance its clinical program with speed, accessibility, cost-effectiveness, including substantial government support, and quality. Coordinating bilateral efforts between the Australian and Indonesian governments and industry experts will provide Recce with market entry and penetration for international expansion opportunities.
Laksana Tri Handoko, Chairman of BRIN, added, “Health science and biomedicine is an important area in Indonesia’s research and innovation. We need to build a national capability, especially after the lesson of the recent pandemic. This collaboration is a continuation of the close relationship we have with Australia, which I see will grow moving forward. We want to build our expertise together and I look forward to the work starting with us.”
There is a significant need for new therapeutics in Indonesia, with the government increasing its focus on addressing infectous diseases and AMR. Specifically, more than 10% of Indonesia's adult population (19.5 million) have diabetes,2 a disease that can lead to higher probabilities of foot, urinary tract, and surgical site infections.3 Furthermore, a recent study showed that 15% of patients with sepsis in Indonesian hospitals had diabetes.4
James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “This Bilateral Collaboration between Recce and Etana signifies the Australian and Indonesian governments’ shared commitment to advancing public health, fostering innovation, and addressing the global challenge of AMR in the Asia Pacific region. By combining our expertise and resources, we can make significant strides towards a healthier and more resilient future for both our nations and the global community.”
About Recce Pharmaceuticals Ltd
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
Media & Investor Relations (AU)
Investor Relations (USA & EU)